Real-World Patient Characteristics, Treatment Patterns, and Outcomes Among Patients with Advanced Cutaneous Squamous Cell Carcinoma Treated with Cemiplimab at US Oncology Clinical Practices

Main Article Content

Wenzhen Ge
Ning Wu
Chieh-I Chen
Timothy J. Inocencio
Patrick R. LaFontaine
Frank Seebach
Matthew Fury
James Harnett
Emily Ruiz

Keywords

advanced cutaneous squamous cell carcinoma, cemiplimab, real-world data, cohort study

References

1. Karimkhani C, et al. J Am Acad Dermatol. 2015;72:186–187.

2. Rogers HW, et al. JAMA Dermatol. 2015;151:1081–1086.

3. Stratigos AJ, et al. Eur J Cancer. 2020;128:60–82.

4. Schmults CD, et al. JAMA Dermatol. 2013;149:541-547.

5. European Medicines Agency. Libtayo: EPAR - Product information. Available from: https://www.ema.europa.eu/en/documents/productinformation/libtayo-epar-product-information_en.pdf. Accessed March 23, 2023.

6. Regeneron Pharmaceuticals Inc. LIBTAYO® (cemiplimab-rwlc) injection prescribing information. Available from: https://www.regeneron.com/downloads/libtayo_fpi.pdf. Accessed March 23, 2023.

7. Bossi P, et al. J Clin Oncol. 2017;35:9543.

8. Foote MC, et al. Ann Oncol. 2014;25:2047–2052.

9. Gold KA, et al. Cancer. 2018;124:2169–2173.

10. Jarkowski AI, et al. Am J Clin Oncol. 2016;39:545–548.

11. Maubec E, et al. J Clin Oncol. 2011;29:3419–3426.

12. Picard A, et al. JAMA Dermatol. 2017;153:291–298.

13. Sun L, et al. JAMA Dermatol. 2019;155:442–447.

14. William WN, Jr., et al. J Am Acad Dermatol. 2017;77:1110–1113.e2.

15. Cowey CL, et al. Cancer Med. 2020;9:7381–7387.

16. Ma X, et al. medRxiv. 2020:2020.03.16.20037143.

17. Migden MR, et al. Lancet Oncol. 2020;21:294–305.

18. Migden MR, et al. N Engl J Med. 2018;379:341–351.

19. Rischin D, et al. J Immunother Cancer.. 2020;8:e000775.

20. Rischin D, et al. J Immunother Cancer. 2021;9:e002757.

Article Sidebar

PDF
Published
Jan 16, 2024
DOI https://doi.org/10.25251/skin.8.supp.338

Article Details

How to Cite
[1]
Ge, W., Wu, N., Chen, C.-I., Inocencio, T.J., LaFontaine, P.R., Seebach, F., Fury, M., Harnett, J. and Ruiz, E. 2024. Real-World Patient Characteristics, Treatment Patterns, and Outcomes Among Patients with Advanced Cutaneous Squamous Cell Carcinoma Treated with Cemiplimab at US Oncology Clinical Practices. SKIN The Journal of Cutaneous Medicine. 8, 1 (Jan. 2024), s338. DOI:https://doi.org/10.25251/skin.8.supp.338.
Issue
Vol. 8 No. 1 (2024): January 2024 Issue
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2